Lawyers Selin Sinem Erciyas

Selin Sinem Erciyas

Selin Sinem Erciyas

Gün + Partners

Selin Sinem Erciyas joined Gün + Partners in 2006 and became a partner in 2014. She specializes in life sciences and intellectual property with a special focus on patents and utility models.

Selin has been involved in a number of advisory and litigation matters in all fields of IP and has handled hundreds of contentious and non-contentious administrative oppositions and court actions involving intellectual property rights, particularly in relation with protection of patent rights. She regularly advises on patent infringement actions, declaration of non-infringement actions and nullity actions.

She represents multinational pharmaceutical companies before the Ministry of Health on regulatory issues and examinations.

Selin is the spokesperson for some NGOs in Turkey and in Europe and represents these NGOs before the Turkish Parliament and Turkish Ministries. Delegation of the European Union to Turkey contacts with Selin every year before drafting the IP section of the EU Progress Report of Turkey. Selin also advises commercial counselors of Embassy of U.S.A, the British Embassy, and the Embassy of Switzerland in relation with the IP Law and developments in Turkey.


Practice Areas & Work Department

Intellectual Property

Patent and Utility Models

Life Sciences


Languages

English

Turkish

German


Memberships

International Federation of Intellectual Property Attorneys Turkey (FICPI Turkey), Founder and President

International Federation of Intellectual Property Attorneys (FICPI)

Association Internationale pour la Protection de la Propriété Intellectuelle (AIPPI), Standards and Patents Committee

German Association for the Protection of Intellectual Property (GRUR)

Istanbul Arbitration Center (ISTAC), Intellectual Property Working Commission

ABAD’ın C-339/22 Sayılı Kararı ve Brussels Ibis m.71(3)’ün AB Üyesi Olmayan Devletler Açısından Yargı Yetkisi Sonuçları: Birleşik Krallık, Norveç, İsviçre ve Türkiye Örneği

Birleşik Patent Mahkemesi’nin (UPC) Avrupa patentlerinin ihlali veya geçerliliğine ilişkin vereceği kararlar, AB üyesi olmayan devletlerin ulusal mahkemeleri açısından bağlayıcı değildir. Bu durum, uluslararası mahkemelerin yalnızca üye devletler bakımından yargı yetkisi kurabileceğini öngören “yerellik ilkesi” ile uyumludur.

22.05.2025

Jurisdictional Implications of CJEU Case C-339/22 and Article 71(3) of Brussels Ibis for Non-EU States: The Case of the UK, Norway, Switzerland and Türkiye

Decisions of the Unified Patent Court (UPC) on the infringement or validity of a European patent are not binding on the national courts of non-EU countries, including the United Kingdom, Norway, Switzerland, and Türkiye.

14.05.2025

The Electrolux - BSH Decision of the CJEU: The Next Step for Jurisdiction in European and Global Patent Infringement Cases

On February 25, 2025, the Court of Justice of the European Union (CJEU) rendered a groundbreaking judgment in the patent infringement case between BSH Hausgeräte GmbH and Electrolux AB, marking a significant ruling not only in Europe but worldwide.

11.04.2025

Birleşik Patent Mahkemesi’nin “Uzun Kolu” Türkiye’ye Uzanır Mı?

Birleşik Patent Mahkemesi'ni kuran Anlaşma yıllar süren çaba sonucunda 2013 yılında Avrupa Birliği üyesi devletlerin çoğunluğu tarafından imzalandı ve 1 Haziran 2023’de yürürlüğe girdi.

27.01.2025

Does the ‘Long Arm’ of the UPC Reach Turkey?

Selin Sinem Erciyas and Zeynep Çağla Üstün explore whether Turkey, as a non-EU state party to the European Patent Convention, might still face the Unified Patent Court’s jurisdiction under EU regulations.

21.01.2025

Yapay Zeka ve İlaç Endüstrisi: Geleceği Şekillendiren Teknoloji ve Patent Sistemindeki Dönüşüm

Yapay zeka, hayatımızın her alanına etki ederek pek çok sektörde olduğu gibi ilaç endüstrisinde de devrimsel etkiler yaratmaktadır.

27.11.2024

Artificial Intelligence and Pharmaceutical Industry: The Transformation in the Technology and Patent System Shaping the Future

Artificial intelligence influences every aspect of our lives and creates revolutionary effects in the pharmaceutical industry as well as in many other sectors. From DeepMind's AlphaGo success to Tempus' personalized approaches to cancer treatment, AI-enabled innovations offer ...

25.11.2024

İlaç Endüstrisinde Yapay Zeka Destekli Patentler

Yeni bir reçeteli ilacın geliştirilmesi pahalı ve uzun bir süreçtir. Tufts İlaç Geliştirme Araştırma Merkezi’nin bir çalışmasına göre, bir ilacın piyasaya sürülmesinin tahmini maliyeti yaklaşık 2,558 milyar dolardır.

19.11.2024
Load More
Ready to stay ahead of the curve?
Share your interest anonymously and let us guide you through the informative articles on the hottest legal topics.
|
Successful Your message has been sent